Breaking News Instant updates and real-time market news.

HMNY

Helios and Matheson

$0.05

0.0004 (0.81%)

, SMH

Market Vectors Semiconductor

$105.74

0.08 (0.08%)

08:45
08/14/18
08/14
08:45
08/14/18
08:45

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: Helios and Matheson (HMNY) 37.88% +3.26, Market Vectors Semiconductor (SMH) 2.21% +1.06, Jack in the Box (JACK) 1.19% +0.94, Majesco (COOL) 43.51% +0.45, JP Morgan (AMJ) 1.80% +0.21, Philip Morris (PM) 0.58% +0.15, BP (BP) 1.08% +0.12, Freeport McMoRan (FCX) 0.85% +0.07, Gogo (GOGO) 18.81% +0.04, and FAS (FAS) 1.36% +0.03.

HMNY

Helios and Matheson

$0.05

0.0004 (0.81%)

SMH

Market Vectors Semiconductor

$105.74

0.08 (0.08%)

JACK

Jack in the Box

$89.03

-1.46 (-1.61%)

COOL

PolarityTE

$24.24

0.47 (1.98%)

AMJ

American Medical Laboratories Inc

$28.91

-0.57 (-1.93%)

PM

Philip Morris

$81.86

-0.68 (-0.82%)

BP

BP

$42.69

-0.295 (-0.69%)

FCX

Freeport McMoRan

$14.92

-0.18 (-1.19%)

GOGO

Gogo

$4.37

0.09 (2.10%)

HMNY Helios and Matheson
$0.05

0.0004 (0.81%)

07/29/18
EROP
07/29/18
DOWNGRADE
EROP
Neutral
Helios and Matheson downgraded to Neutral from Buy at Euro Pacific
04/25/18
MAXM
04/25/18
INITIATION
Target $12
MAXM
Buy
Helios and Matheson assumed with a Buy at Maxim
Maxim analyst Nehal Chokshi assumed Helios and Matheson with a Buy rating but lowered his price target to $12 from $16 under the prior coverage. The analyst contends that survey findings suggest "overusage being contained to a sliver of subscribers" and believes the company can trade at $12 per share based on enterprise value of $1.4B is its MoviePass offering can show incremental traffic from occasional movie goers hitting just 1 movie ticket per month.
07/26/18
MAXM
07/26/18
INITIATION
MAXM
Hold
Helios and Matheson assumed with a Hold at Maxim
Maxim analyst Allen Klee assumed Helios and Matheson with a Hold rating, saying that while he remains optimistic about the potential for continued MoviePass subscriber growth, he is also cautious about the company's potential capital raising needs. Klee also sees the stock as a "high risk/reward" situation as it trades at 0.1-times his expected FY18 revenue estimate.
04/24/18
ADAM
04/24/18
NO CHANGE
Target $12
ADAM
Buy
Helios and Matheson price target lowered to $12 from $15 at Canaccord
Canaccord analyst Austin Moldow lowered his price target on Helios and Matheson to $12 from $15 following its recent capital raise. The analyst raised his revenue forecast, but it was more than offset by the higher share count given the company's capital raise and its at-the-market offering, where the company can sell shares in the open market at its discretion. Moldow maintained his Buy rating on Helios and Matheson shares.
SMH Market Vectors Semiconductor
$105.74

0.08 (0.08%)

JACK Jack in the Box
$89.03

-1.46 (-1.61%)

07/11/18
WEDB
07/11/18
NO CHANGE
Target $115
WEDB
Outperform
Jack in the Box added to Best Ideas List at Wedbush
Wedbush analyst Nick Setyan added Jack in the Box to his firm's Best Ideas List, while reiterating an Outperform rating and $115 price target on the stock. The analyst views the combination of long-term same-store sales growth, margin, and free cash flow guidance, expected in August, and incremental visibility into short- and medium-term same-store sales growth drivers, beginning with solid Q4 same-store sales growth guidance, to result in an upward revaluation of shares.
05/18/18
RHCO
05/18/18
NO CHANGE
Target $100
RHCO
Buy
Jack in the Box price target lowered to $100 from $110 at SunTrust
SunTrust analyst Jake Bartlett lowered his price target on Jack in the Box to $100 after the company's lowered FY18 SSS forecast, saying it adds uncertainty to the prospects of recovery in comps on top of the uncertainty around cost savings. Longer term, Bartlett keeps his Buy rating despite the increased risk, noting that its free cash flow yield per share of 7.7% is attractive while its post Qdoba-sale and refranchising investment story is "compelling".
05/10/18
SPHN
05/10/18
NO CHANGE
Target $120
SPHN
Overweight
GrubHub deal with Jack in the Box 'one of many to come,' says Stephens
After GrubHub (GRUB) announced a partnership to provide delivery for hundreds of Jack in the Box (JACK) locations, Stephens analyst Will Slabaugh noted that the deal is not exclusive but he believes it will be "one of many to come" for GrubHub with large national chains. He maintains an Overweight rating and $120 price target on GrubHub shares.
05/07/18
05/07/18
DOWNGRADE

Mixed
Follow-up: Jack in the Box downgraded to Mixed on competition at OTR Global
As previously reported, OTR Global downgraded Jack in the Box to Mixed from Positive. The firm's checks with managers indicate increased competition and a mixed response to the Cholula Buttery Jack is pressuring transactions and sales.
COOL PolarityTE
$24.24

0.47 (1.98%)

06/25/18
CANT
06/25/18
NO CHANGE
Target $65
CANT
Overweight
Cantor reiterates Overweight rating on PolarityTE after meeting with doctors
After attending an event hosted by PolarityTE with Key Opinion Leaders and hearing three surgeons describe their clinical experiences using SkinTE, Cantor Fitzgerald analyst Elemer Piros said he believes PolarityTE is positioned long-term to "redefine the treatment landscape for wound regeneration." He believes the fact that the shares are trading down 33% may be due to the market's misunderstanding of the company's IP strategy and interaction with the U.S. Patent and Trademark Office. Piros' note to investors makes no mention of Citron Research, which earlier today accused PolarityTE of fraud related to its patent holdings and promotion of the patents to investors. Piros reiterates his Overweight rating and $65 price target on PolarityTE, which is down 32% to $26.42 in afternoon trading.
06/27/18
CANT
06/27/18
NO CHANGE
Target $65
CANT
Overweight
Cantor says PolarityTE patent process ongoing, commercialization maturing
After hosting a conference call with PolarityTE management yesterday, Cantor Fitzgerald analyst Elemer Piros said that the company walked through the process of its interaction with the USPTO and explained that the patent process is ongoing, not finalized, and may take years. Meanwhile, SkinTE was commercialized in December 2017 via a limited market release and the company's commercialization efforts are maturing, said Piros, who reiterates an Overweight rating and $65 price target on PolarityTE shares.
02/15/18
02/15/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Portland General Electric (POR) initiated with a Buy at Mizuho. 2. Arsanis (ASNS) initiated with an Overweight at Cantor Fitzgerald. 3. Cantor says PolarityTE (COOL) can revolutionize regenerative medicine. 4. Foundation Medicine (FMI) initiated with an Outperform at Cowen. 5. Box (BOX) initiated with a Buy at DA Davidson. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
06/13/18
CANT
06/13/18
NO CHANGE
Target $65
CANT
Overweight
PolarityTE price target lowered to $65 from $70 at Cantor Fitzgerald
Cantor Fitzgerald analyst Elemer Piros lowered his price target for PolarityTE to $65 to reflect the company's recent financing. The analyst, however, left an investor tour at the company's Salt Lake City facilities with significant confidence for its "extensive" pipeline. The analyst believes PolarityTE looks well positioned to deliver on its objectives over the next 24 months. He reiterates an Overweight rating on the shares.
AMJ American Medical Laboratories Inc
$28.91

-0.57 (-1.93%)

PM Philip Morris
$81.86

-0.68 (-0.82%)

07/25/18
ARGS
07/25/18
UPGRADE
ARGS
Buy
Philip Morris upgraded to Buy from Hold at Argus
07/23/18
07/23/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Papa John's (PZZA) downgraded to Sell from Hold at Stifel with analyst Chris O'Cull saying the outlook for Papa John's is "growing dimmer" after recent media reports indicated a "fraternal corporate culture." 2. Buckeye Partners (BPL) downgraded to Sell from Hold at SunTrust with analyst Tristan Richardson saying the latest negative action by Moody's was "quicker than expected" and may lead to a cut in the company's distribution. 3. Walgreens Boots Alliance (WBA) downgraded to Market Perform from Outperform at Cowen with analyst Charles Ryhee saying he views it as poorly positioned in the move toward value-based care and believes the ownership of, rather than a partnership with, an insurance company is necessary to realize the benefits of cost trend improvements. 4. General Electric (GE) downgraded to Hold from Buy at Argus with analyst John Eade saying that despite his expectations of a turnaround, Q2 results were a "step in the opposite direction" suggesting the company will struggle to meet its FY18 guidance. 5. Philip Morris (PM) downgraded to Hold from Buy at Societe Generale. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
07/25/18
ARGS
07/25/18
UPGRADE
Target $91
ARGS
Buy
Philip Morris upgraded to Buy at Argus on strong business trends
As reported earlier, Argus analyst David Coleman upgraded Philip Morris to Buy from Hold with a price target of $91. The analyst says the company's core businesses remain strong, while its brands are expected to generate "premium prices". Coleman also cites the efforts by Philip Morris to develop cigarette alternatives with reduced risk such as heated tobacco units, which is promising amid the increasing health awareness and regulation environment. The analyst also believes that the stock is attractively valued based on its historical P/E, and price-cash flow multiples.
08/01/18
MSCO
08/01/18
NO CHANGE
MSCO
Deep discount cigarette share gains add to pricing worries, says Morgan Stanley
Morgan Stanley analyst Pamela Kaufman said the "deep discount" cigarette segment has gained U.S. market share in four out of the last five quarters. Smokers are trading down despite the healthy consumer environment and despite Altria Group's (MO) stepped up spending, noted Kaufman, who added that widening Marlboro price gaps could pressure net pricing realization. The last time Marlboro consistently lost market share in 2011, Altria responded with meaningfully less pricing growth, noted Kaufman. She has an Equal Weight rating and $63 price target on Altria and an Overweight rating and $102 price target on Philip Morris (PM).
BP BP
$42.69

-0.295 (-0.69%)

07/09/18
RBCM
07/09/18
UPGRADE
RBCM
Top Pick
BP upgraded to Top Pick from Outperform at RBC Capital
RBC Capital analyst Biraj Borkhataria upgraded BP to Top Pick from Outperform with a price target of GBP 675, saying the company's visibility for volume growth will lead to higher cash flows from operations. The analyst adds that BP has "one of the stronger growth profiles from now to 2020 among the majors" with further growth options beyond, while its liability payments from the Macondo disaster are diminishing as claims are reduced. Borkhataria also sees BP benefiting from wider crude spreads.
07/31/18
UBSW
07/31/18
NO CHANGE
Target $26
UBSW
Buy
Diamond Offshore price target raised to $26 from $22 at UBS
UBS analyst Sasha Sanwal raised his price target on Diamond Offshore (DO) to $26 from $22 following its contract win with British Petroleum (BP) and Anadarko (APC). He called it a landmark event for the company and the industry as the contract serve as a validation of its success in creating a differentiated platform by two of the biggest players in offshore. Sanwal reiterated his Buy rating on Diamond Offshore shares.
08/09/18
GSCO
08/09/18
UPGRADE
GSCO
Conviction Buy
BP upgraded to Conviction Buy from Buy at Goldman Sachs
07/09/18
07/09/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. FireEye (FEYE) upgraded to Overweight from Neutral at Piper Jaffray with analyst Andrew Nowinski saying a recent round of channel checks showed a "significant improvement" in demand trends for the company. 2. BP (BP) upgraded to Top Pick from Outperform at RBC Capital with analyst Biraj Borkhataria saying the company's visibility for volume growth will lead to higher cash flows from operations. 3. Capital One (COF) upgraded to Outperform from Perform at Oppenheimer with analyst Ben Chittenden saying the delinquency formation is improving and Q2 expectations seem too low to him. 4. Dunkin' Brands (DNKN) upgraded to Neutral from Underperform at Longbow with analyst Alton Stump saying his conversations with U.S. franchisees lead him to believe the company's Q2 same-store sales rose 0.5-1.0%, which would be in-line with the consensus view and slightly better than his prior forecast for them to have been flat with last year. 5. Baidu (BIDU) upgraded to Outperform from Neutral at Credit Suisse and to Overweight from Sector Weight at KeyBanc. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
FCX Freeport McMoRan
$14.92

-0.18 (-1.19%)

07/26/18
07/26/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Dana (DAN) upgraded to Overweight from Equal Weight at Barclays with analyst Brian Johnson citing the company's Q2 results. 2. Xilinx (XLNX) upgraded to Buy from Neutral at Rosenblatt and to Buy from Underperform at BofA/Merrill. 3. Freeport McMoRan (FCX) upgraded to Hold from Sell at Deutsche Bank with analyst Chris Terry saying he believes the risks are now priced into the shares. 4. Integra LifeSciences (IART) upgraded to Buy from Neutral at BTIG with analyst Ryan Zimmerman saying the pullback in the stock price after its in-line Q2 results has created a more attractive valuation. 5. Cracker Barrel (CBRL) upgraded to Buy from Hold at Maxim with analyst Stephen Anderson saying he sees more stable comps and lower food costs helping the company return to low-teen earnings growth. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
08/02/18
BOFA
08/02/18
UPGRADE
Target $17
BOFA
Neutral
Freeport McMoRan upgraded to Neutral from Underperform at BofA/Merrill
BofA/Merrill analyst Timna Tanners upgraded Freeport McMoRan to Neutral from Underperform and maintained a $17 price target citing valuation, reduced political risk at Grasberg, and a more constructive view on copper.
08/02/18
08/02/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Tesla (TSLA) upgraded to Outperform from Perform at Oppenheimer with analyst Colin Rusch saying gross margin performance on the Model 3 will carry the stock over the next 12-plus months. 2. Freeport McMoRan (FCX) upgraded to Neutral from Underperform at BofA/Merrill with analyst Timna Tanners citing valuation, reduced political risk at Grasberg, and a more constructive view on copper. 3. EnLink Midstream Partners (ENLK) upgraded to Buy from Hold at Stifel with analyst Timothy Howard citing the company's Q2 results that topped his expectations and raised 2018 guidance, which also lifted expectations in 2019. 4. Univar (UNVR) upgraded to Conviction Buy from Buy at Goldman Sachs with analyst Roert Koort saying the weakness following the in line Q2 report and reaffirmed 2018 guidance is "unwarranted." 5. Qorvo (QRVO) upgraded to Hold from Sell at Summit Insights with analyst Kinngai Chan citing the Q2 report saying investor expectations were high going into the report and now expects shares to perform in-line. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
08/06/18
MSCO
08/06/18
NO CHANGE
MSCO
Boeing, Tesla, Nvidia make Morgan Stanley 'key man risk' list
Morgan Stanley equity strategist Mark Savino noted that about 12% of CEO jobs among S&P 500 companies turned over in 2017, noting that this was the highest level of CEO departures since before the financial crisis. The 59 stocks of S&P 500 companies that had CEOs depart in 2017 underperformed the market by 11% over the next 12 months, or since the departure for instances that were less than 12 months ago, noted Savino. In cooperation with the firm's U.S. analysts, Savino and his team identified the companies in each sector they believe face the greatest level of "key man risk," which includes: Boeing (BA), Tesla (TSLA), ADT Inc. (ADT), Moody's (MCO), TransUnion (TRU), Arista Networks (ANET), Church & Dwight (CHD), Coca-Cola (KO), Monster Beverage (MNST), Coupa Software (COUP), Salesforce (CRM), FireEye (FEYE), MongoDB (MDB), Microsoft (MSFT), New Relic (NEWR), XPO Logistics (XPO), Hilton (HLT), Las Vegas Sands (LVS), Best Buy (BBY), Ulta (ULTA), Aflac (AFL), Athene Holding (ATH), Lincoln National (LNC), Arthur J. Gallagher (AJG), Chubb (CB), Amazon.com (AMZN), Activision Blizzard (ATVI), Facebook (FB), Alphabet (GOOGL), Apple (AAPL), Terex (TEX), Cleveland-Cliffs (CLF), Freeport McMoRan (FCX), FleetCor (FLT), Global Payments (GPN), Square (SQ), Jazz Pharmaceuticals (JAZZ), Cheesecake Factory (CAKE), Broadcom (AVGO), Nvidia (NVDA), Chegg (CHGG), DXC Technology (DXC), Medidata (MDSO), Pluralsight (PS), RealPage (RP), Shopify (SHOP) and T-Mobile (TMUS).
GOGO Gogo
$4.37

0.09 (2.10%)

07/17/18
WBLR
07/17/18
DOWNGRADE
WBLR
Market Perform
William Blair downgrades Gogo on risk of trading to $1 range
William Blair analyst Louie DiPalma downgraded Gogo to Market Perform from Outperform saying he "misjudged" the company's ability to improve the profitability of its commercial division in the near term. Last Friday's update conference call revealed that the substantial cost reductions expected in the near term are not anticipated until late 2020, DiPalma tells investors in a research note. While the stock has potential upside with the right strategic transaction, there is risk that it trades down to the $1 range or lower with multiple compression, the analyst adds. Gogo shares closed yesterday at $3.76.
07/24/18
07/24/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Whirlpool (WHR) downgraded to Neutral from Buy at Longbow with analyst David MacGregor calling its quarter "disappointing across most dimensions of the business." 2. Gogo (GOGO) downgraded to Market Perform from Outperform at Raymond James with analyst Ric Prentiss saying he expects several more quarters of "turbulence" given potential dilution/rollover risks from 2020 bond convertible bond maturities, churn pressures, continued negative free cash flow, and the airline industry shift to directed pricing. 3. Marriott (MAR) downgraded to Equal Weight from Overweight at Morgan Stanley with analyst Thomas Allen saying he is more bullish on the Gaming REITs, given their attractive, dependable yields, and has become more cautious on Lodging, he tells investors. 4. Infinera (INFN) downgraded to Underperform from Market Perform at Raymond James. 5. Hasbro (HAS) downgraded to Neutral from Buy at Monness Crespi. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
07/24/18
07/24/18
DOWNGRADE

Market Perform
Gogo downgraded to Market Perform on continued 'turbulence' at Raymond James
As previously reported, Raymond James downgraded Gogo to Market Perform from Outperform. Analyst Ric Prentiss expects several more quarters of "turbulence" given potential dilution/rollover risks from 2020 bond convertible bond maturities, churn pressures, continued negative free cash flow, and the airline industry shift to directed pricing.
07/24/18
RAJA
07/24/18
DOWNGRADE
RAJA
Market Perform
Gogo downgraded to Market Perform from Outperform at Raymond James

TODAY'S FREE FLY STORIES

TIF

Tiffany

$126.28

0.7 (0.56%)

16:55
09/25/18
09/25
16:55
09/25/18
16:55
Hot Stocks
Tiffany director Fish sells 6,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 27

    Sep

ABBV

AbbVie

$93.78

0.34 (0.36%)

16:52
09/25/18
09/25
16:52
09/25/18
16:52
Hot Stocks
AbbVie approved for VENCLEXTAR/Rituximab leukemia treatment in Canada »

AbbVie announced Health…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

CONE

CyrusOne

$64.65

-0.6 (-0.92%)

16:51
09/25/18
09/25
16:51
09/25/18
16:51
Syndicate
CyrusOne 8M share Spot Secondary; price range $62.00-$64.00 »

Morgan Stanley, Deutsche…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Oct

CHGG

Chegg

$32.34

0.92 (2.93%)

16:50
09/25/18
09/25
16:50
09/25/18
16:50
Hot Stocks
Chegg says unauthorized party gained access to a company database »

On September 19, Chegg…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

EGY

VAALCO Energy

$2.59

0.14 (5.71%)

16:47
09/25/18
09/25
16:47
09/25/18
16:47
Hot Stocks
VAALCO Energy announces 10-year extension of Etame exploration area »

VAALCO Energ through its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MGM

MGM Resorts

$27.86

-0.05 (-0.18%)

16:40
09/25/18
09/25
16:40
09/25/18
16:40
Options
Calls lead puts 30:1 in MGM as long call position is adjusted »

Calls lead puts 30:1 in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Oct

NNI

Nelnet

$56.82

-0.79 (-1.37%)

16:38
09/25/18
09/25
16:38
09/25/18
16:38
Hot Stocks
Nelnet withdraws application for industrial bank charter with FDIC »

Nelnet announced it has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:38
09/25/18
09/25
16:38
09/25/18
16:38
General news
API crude inventories for week of September 21 »

API reports that crude…

IGT

International Game

$19.91

0.23 (1.17%)

16:37
09/25/18
09/25
16:37
09/25/18
16:37
Hot Stocks
International Game partners with William Hill on U.S. lotteries »

IGT Global Solutions, a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SGMS

Scientific Games

$26.45

0.15 (0.57%)

16:34
09/25/18
09/25
16:34
09/25/18
16:34
Hot Stocks
Scientific Games signs contract with Hard Rock International »

Scientific Games…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DGLY

Digital Ally

$3.75

-0.275 (-6.83%)

16:33
09/25/18
09/25
16:33
09/25/18
16:33
Syndicate
Digital Ally files to sell common stock, no amount given »

Roth Capital Partners is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

R

Ryder

$72.75

-0.04 (-0.05%)

16:33
09/25/18
09/25
16:33
09/25/18
16:33
Hot Stocks
Ryder CFO Art Garcia to retire in April 2019 »

Ryder announced that Art…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

BZH

Beazer Homes

$11.08

-0.015 (-0.14%)

16:33
09/25/18
09/25
16:33
09/25/18
16:33
Hot Stocks
Beazer says Hurricane Florence will result in sales, closings shifting to FY19 »

Beazer Homes provided an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MCO

Moody's

$172.88

-2.66 (-1.52%)

16:31
09/25/18
09/25
16:31
09/25/18
16:31
Hot Stocks
Moody's appoints Mona Breed as CIO »

Moody's announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 27

    Sep

  • 28

    Sep

  • 02

    Oct

  • 21

    Oct

FCFS

First Cash Financial

$83.03

0.625 (0.76%)

16:31
09/25/18
09/25
16:31
09/25/18
16:31
Hot Stocks
First Cash Financial announces move to Nasdaq from NYSE »

FirstCash announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

  • 06

    Nov

OKE

Oneok

$68.44

0.565 (0.83%)

16:31
09/25/18
09/25
16:31
09/25/18
16:31
Hot Stocks
Oneok to construct additional NGL fractionation, pipeline capacity »

Oneok announced plans to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:30
09/25/18
09/25
16:30
09/25/18
16:30
Options
Preliminary option volume of 15.6M today »

Preliminary option volume…

MOR

MorphoSys

$27.13

0.315 (1.17%)

16:28
09/25/18
09/25
16:28
09/25/18
16:28
Hot Stocks
MorphoSys says licensee has begun study to test gselkumab in pediatric group »

MorphoSys announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NITE

Nightstar Therapeutics

$20.35

-0.97 (-4.55%)

16:26
09/25/18
09/25
16:26
09/25/18
16:26
Syndicate
Nightstar Therapeutics files to sell 4M American Depositary Shares »

Jefferies, Barclays…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Oct

NITE

Nightstar Therapeutics

$20.35

-0.97 (-4.55%)

16:24
09/25/18
09/25
16:24
09/25/18
16:24
Syndicate
Nightstar Therapeutics files to sell 4M American Depositary Shares »

Each ADS represents one…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Oct

VSTM

Verastem

$7.15

-1.74 (-19.57%)

16:23
09/25/18
09/25
16:23
09/25/18
16:23
Hot Stocks
Breaking Hot Stocks news story on Verastem »

Verastem rises over 5%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Oct

  • 05

    Oct

ICCC

Immucell

$8.35

-0.155 (-1.82%)

16:22
09/25/18
09/25
16:22
09/25/18
16:22
Hot Stocks
Immucell looks to bring mastitis treatment to market in 2020 »

ImmuCell announced an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

ICCC

Immucell

$8.35

-0.155 (-1.82%)

16:22
09/25/18
09/25
16:22
09/25/18
16:22
Hot Stocks
Immucell receives fourth complete letter of NADA for Nisin treatment for cows »

Immucell announced a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

VSTM

Verastem

$7.15

-1.74 (-19.57%)

16:21
09/25/18
09/25
16:21
09/25/18
16:21
Hot Stocks
Verastem and CSPC Pharma sign license agreement to develop COPIKTRA in China »

Verastem and CSPC…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Oct

  • 05

    Oct

LOXO

Loxo Oncology

$166.80

3.73 (2.29%)

16:21
09/25/18
09/25
16:21
09/25/18
16:21
Hot Stocks
Loxo Oncology announces LOXO-292 durability update »

Loxo Oncology announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 26

    Sep

  • 26

    Nov

  • 27

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.